Presentation and Status in Health Basket
50 X 25 mg
Reduced efficiency and potency disturbances
Commencement of treatment: 1 Proviron tablet 3 times per day. After satisfactory clinical improvement, it can be tried to reduce the dose.
Continuation of treatment: 1 Proviron tablet twice or once per day. According to the type and severity of the complaints, the dose for further treatment is to be adjusted to individual requirements. Continuous treatment over a period of several months is recommended.
Hypogonadism requires continuous therapy: For development of secondary male sex characteristics, 1 – 2 Proviron tablets 3 times per day for several months. As maintenance dose, 1 Proviron tablet 2 – 3 times per day will often be sufficient.
Infertility – for the improvement of sperm quantity and quality: 1 Proviron tablet 2 – 3 times per day for a cycle of spermatogenesis, i.e. for about 90 days. If necessary, Proviron treatment is to be repeated after an interval of several weeks. To achieve a higher fructose concentration in the ejaculate in cases of postpuberal Leydig-cell insufficiency: 1 Proviron tablet twice per day over several months.
Androgen therapy: reduced efficiency in middle and advanced age, potency disturbances, hypogonadism, infertility.
Prostatic carcinoma. Previous or existing liver tumours.
NOTE: Androgens are not suitable for enhancing muscular development in healthy individuals or for increasing physical ability.
Risk of carcinoma: The occasionally expressed fear that prostatic carcinoma can be induced by the use of androgens is unfounded. Androgens have no carcinogenic action. Observations made over many years have shown that the risk of carcinoma in men treated with androgens was no greater than in an untreated control group. Specific studies of male patients under long-term and high-dosed therapy with testosterone produced no signs of prostatic carcinoma and, hence, no evidence that the exogenous supply of testosterone activates any atypical cells which may be present. The regular check-ups during the therapy failed to reveal a single case of carcinoma among patients with prostatic adenoma, whose complaints were favourably influenced by Proviron. Since androgens can exacerbate a clinically manifest carcinoma of the prostate, malignant tumours of the prostate must be ruled out before the start of Proviron treatment. As in prophylactic examinations of men, regular rectal and – if required to confirm the diagnosis – biopsy examinations must be carried out during the therapy.
Liver tumours: In rare cases, benign, and in even rarer cases, malignant liver tumours leading in isolated cases to life-threatening intra-abdominal haemorrhage have been observed after the use of hormonal substances such as the one contained in Proviron. A liver tumour should be included in the differential-diagnostic considerations if severe upper abdominal complaints, a liver enlargement or signs of an intra-abdominal haemorrhage occur. If necessary, the preparation must be withdrawn.
Proviron is well tolerated even as regards liver function. Laboratory tests conducted during high-dosed and long-term treatment produced no evidence for an injurious effect. If, in individual cases, frequent or persistent erections occur, the dose should be reduced or the treatment discontinued in order to avoid injury to the penis.
None recorded so far.
Acute toxicity studies using single administration showed that Proviron is to be classified as practically non-toxic. No risk of toxicity is to be expected even after inadvertent single administration of a multiple of the dose required for therapy.